Saw Palmetto (Serenoa repens) is the cornerstone botanical of nearly every prostate-support supplement on the market, and it's been the subject of a remarkable amount of clinical research over the last 30 years. It's also the subject of a polarised literature, with some studies showing meaningful effects and others showing nothing.

This article is our attempt to walk through the evidence honestly — what's solid, what's marginal, and what's sales material.

The mechanism, briefly

Saw Palmetto's clinically active compounds are concentrated in the lipidosterolic extract — the fat-soluble fraction extracted from the berries. The primary actives include:

  • Free fatty acids (palmitic, oleic, lauric)
  • Beta-sitosterol and other plant sterols
  • Smaller quantities of other phytochemicals

The proposed mechanism is multi-layered. Saw Palmetto appears to weakly inhibit 5-alpha-reductase (the enzyme that converts testosterone to DHT) in prostate tissue specifically — far less potently than prescription drugs like finasteride, but in a way that contributes to reduced DHT exposure in the prostate over time. It also appears to have anti-inflammatory effects on prostate tissue and may modestly affect androgen receptor binding.

The effect on each individual mechanism is small. The combined effect over months of consistent use is more than the sum.

The literature, honestly

The positive trials

The European Permixon trials (using a specific lipidosterolic extract at 320mg/day) consistently show modest but statistically significant improvements in IPSS scores, urinary flow rates, and nocturia frequency over 6-12 month courses. Meta-analyses by the Cochrane group and others have variably interpreted this body of evidence, but the U.S. medical community's broad consensus is that Permixon-grade Saw Palmetto extract is a legitimate first-line option for mild-to-moderate BPH.

The negative trials

The most prominent negative trials — particularly the STEP trial (2006) and CAMUS trial (2011) — used different extracts at different doses and showed no significant difference from placebo. These trials are frequently cited by Saw Palmetto sceptics, and they're real and well-conducted.

What gets lost in the polarised reading: the negative trials didn't necessarily test the same product. Saw Palmetto extracts vary substantially in their fatty-acid composition, processing methods, and active-compound content. The lipidosterolic extract used in Permixon (and similar U.S. products) has a different profile than some of the U.S.-market extracts used in the negative trials.

This isn't a defensive argument; it's a real issue with botanical research generally. "Saw Palmetto" on a label can mean very different things depending on the source.

What the honest synthesis looks like

For a high-quality lipidosterolic extract dosed at 320mg/day, the expected outcomes for men with mild-to-moderate BPH over 6-12 months:

  • Modest reduction in IPSS scores (typical: 2-3 point reduction on the 35-point scale)
  • Small improvement in urinary flow rate (~1-2 mL/sec)
  • Reduction in nocturia frequency (typically by 0.5-1 episode per night)
  • No measurable effect on prostate volume in most studies

These are real but modest changes. For a man with severe BPH, this is unlikely to be sufficient. For a man with mild-to-moderate symptoms, this is often the difference between disrupted nightly sleep and stable sleep.

The standardisation problem

The "Saw Palmetto" you find in most consumer supplement aisles ranges from raw berry powder (essentially worthless) to high-grade lipidosterolic extract standardised to 85-95% fatty acids (the form used in the positive trials). The price difference reflects this — proper extract costs 5-10x what raw powder costs to manufacture.

If you're going to take Saw Palmetto, the form matters far more than the brand. Look for:

  • Lipidosterolic extract (not raw berry powder)
  • Standardised to 85-95% fatty acids (preferably stated explicitly)
  • 320mg/day dose (the Permixon-equivalent dose used in trials)
  • Dose-stable form (typically a softgel or fat-encapsulated capsule, since the actives are fat-soluble)

ProstaRemedy uses the standardised lipidosterolic extract at 320mg/day, the same dose form used in the bulk of the clinical literature.

Side effects and contraindications

Saw Palmetto is exceptionally well-tolerated in clinical trials. Side effects are typically mild and transient — occasional nausea, headache, or GI discomfort, generally indistinguishable from placebo across populations.

Important contraindications:

  • Anti-coagulant therapy — Saw Palmetto has theoretical effects on platelet function. If you're on warfarin or similar, talk to your doctor.
  • Surgery — discontinue at least 2 weeks before any planned surgery for the same reason.
  • Hormone-sensitive conditions — anything involving DHT-related pathways should be discussed with your specialist.

The honest summary

Saw Palmetto isn't a miracle. It's not equivalent to prescription medication. The literature is real but mixed, and quality matters more than most consumers know.

For the right product (high-grade lipidosterolic extract, 320mg/day) used consistently for 12+ weeks in men with mild-to-moderate urinary symptoms, the evidence supports modest but meaningful improvement. That's what we built ProstaRemedy around.

It's a good lever. Not a magic one.